Answers are grounded in this paper and cite their sources.
One year of adjuvant trastuzumab has been the standard treatment for human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer since the mid-2000s. 1 From the outset, the expense and cardiac toxicity associated with trastuzumab use led to questioning of treatment duration (1 year), which was chosen based on a slim scientific base. The results of the FinHER trial, which showed tangible benefits with 9 weeks of trastuzumab treatment, suggest that a shorter and cheaper regimen could still be effective. 2 Later, the lack of added benefit of extended trastuzumab treatment seen in the HERA 2-year arm reinforced the notion of a “ceiling effect”—a point beyond which extending trastuzumab treatment duration does not lead to further improvement in outcomes. 3 The PHARE, 4 HORG, 5 SOLD, 6 SHORT-HER 7 and PERSEPHONE 8 trials were launched to determine whether a shorter regimen would be non-inferior to the standard regimen. Though the first four trial failed to prove non-inferiority, the recently presented non-inferior results of PERSEPHONE have led to considerable debate. Figure 1 depicts the design of these trials and Table 1 summarizes their results. Fig. 1 The alternative text for this image may have been generated using AI. Full size image Shorter duration trials—design & definition of non-inferiority. Legend: 1. R randomization, DFS disease-free survival, HR Hazard Ratio, CI confidence interval, FEC 5-fluorouracil, epiribucin, cyclophosphamide, AC anthracyline, cyclophosphamide, EC epirubicin, cyclophosphamide. Trastuzumab could be combined with or sequential with chemotherapy; 2. Patients could be randomised at any point in time up to the 6th month of treatment. 3. The HRs are calculated with shorter arm relative to longer arm, hence the upper bound of confidence interval HR margin greater than 1.00 indicates the maximum increase in relative risk of a DFS event that would be tolerated in order to declare the shorter duration treatment as non-inferior Table 1 Shorter duration trials—results Full size table
No takes yet. Share an insight, caveat, or question.
Pondé et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: